Cabbacis, Inc. · OTC:CABI
Cabbacis — Investor Presentation (2026)
24 slides from Cabbacis's investor presentation, Sep 21, 2026
Slide 1: Developing Risk Reduction Products for the World's 1 Billion Smokers
Developing Risk Reduction Products for the World’s 1 Billion Smokers Investor Presentation OTCQB: CABI Q4 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by Cabbacis Inc (the “Company”) solely for informational purposes. The information included in this presentation has not been independently verified. No representations, warranties or undertakings, express or implied, are made by the Com
Slide 3: Presenting Today
Presenting Today Joseph Pandolfino Founder & CEO 3
Slide 4: Corporate Overview
Corporate Overview Cabbacis is a tobacco product manufacturer focused on commercializing risk- reduction products – led by the flagship iBlend cigarettes and vaporizer pods. • Developing flagship iBlend products (cigarettes & vaporizer pods containing both very-low-nicotine tobacco and hemp) to help
Slide 5: Reg A Offering
Reg A Offering Cabbacis is raising up to $7.5 Million REG A Offering Investment Terms • Open to accredited and non-accredited • Common Stock U.S. investors • $2.00 per share • Open to anyone outside of the U.S. at or • Up to 3.75 M shares being offered over the age of 18 • No warrants • Fully compli
Slide 6: Experienced Management Team
Experienced Management Team Joseph Pandolfino, Founder and CEO. Joe is the inventor on the company’s patents and leads the strategic direction of Cabbacis. He is also the founder, and was the first CEO, of 22nd Century Group, Inc. (Nasdaq: XXII) and led the process of 22nd Century becoming publicly
Slide 7: Innovative SPECTRUM Research Cigarettes
Innovative SPECTRUM® Research Cigarettes • Proprietary design created by Mr. Pandolfino and Dr. Moynihan • SPECTRUM® government research cigarettes evaluated in more than 4 dozen independent clinical studies • 7 levels of nicotine from very low to conventional • Results demonstrate that subjects smo
Slide 8: Market Opportunity
Market Opportunity Global Tobacco Market U.S. Tobacco Market 3.0% • Cigarettes are ~85% of market 8.2% • 28M adult smokers CAGR ($800B) CAGR • ~200B cigarettes annually $1.1T1 • 1.1B tobacco/nicotine users $180B2 $905B $113B • 5T cigarettes annually including heated tobacco units 2023 2030 ® 2024 20
Slide 9: FDA Plan for Maximum Nicotine Level in Cigarettes
FDA Plan for Maximum Nicotine Level in Cigarettes • January 15, 2025: The U.S. Food and Drug Administration issued a proposed rule 1 that, if finalized, would limit the level of nicotine in cigarettes and certain other combusted tobacco products in the United States • This rule would cap nicotine at
Slide 10: Our Solution: iBlend Botanical Blends
Our Solution: iBlend Botanical Blends iBlend predominately contains tobacco and includes non-intoxicating hemp Low Nicotine Hemp Tobacco Very-Low THC & No-THC Cannabis Nicotine content THC content reduced by ~95% less than 0.3% Company contracts Company contracts directly with directly with farmers
Slide 11: iBlend Product Focus Areas
iBlend Product Focus Areas Very-Low-Nicotine Cigarettes Vaporizers Pods1 1) Three exemplary vaporizers and pods, which are capable of utilizing blends of very-low-nicotine tobacco and hemp, are shown above: IQOS® is a registered trademark of Philip Morris Products S.A; PAX® is a registered trademark
Slide 12: Benefits Inherent to Flagship iBlend Offering
Benefits Inherent to Flagship iBlend Offering Very-Low-Nicotine Cigarettes Very-Low-Nicotine Vaporizer Pods • Assists smokers to smoke less, reduce • iBlend vapor is less harmful than nicotine exposure, and increase quit attempts smoking and not addictive like • Assists smokers to transition to less
Slide 13: Clinical Trial
Clinical Trial Cabbacis contracted the Rose Research Center to carry out a pilot clinical trial on 16 smokers exclusively using four types of very-low-nicotine tobacco cigarettes made by Cabbacis during 3-hour ad libitum use sessions Three iBlend cigarette types contained very-low-nicotine tobacco a
Slide 14: Cabbacis Expects to be First to Market
Cabbacis Expects to be First to Market Company IP Enables Cabbacis to be the Sole Provider of Very-Low- Nicotine Tobacco Products with Hemp in Countries with Patent Protection Relevant to consumers as a Differentiated as the only Not targeted by Big better alternative due to very-low-nicotine tobacc
Slide 15: iBlend U.S. Regulatory Path
iBlend U.S. Regulatory Path Clinical Trials Pre- Post Market Acceptance Filing Review Action • Clinical trial compared very-low-nicotine Meetings Reporting cigarettes without hemp and 3 other styles with varying levels of hemp • Dr. Jed Rose, coinventor of the nicotine patch, was the trial’s Primary
Slide 16: Manufacturing Facility & Licenses
Manufacturing Facility & Licenses 5,200 sq. ft. facility is strategically located within a large manufacturing complex • Cabbacis has access to additional ~8,000 sq. ft. of hemp growing facilities and ~6,000 sq. ft. of GMP Certified processing/storage areas • Hemp growing operations are closely foll
Slide 17: Worldwide Patent Protection
Worldwide Patent Protection 36 Issued Patents Including 8 U.S. Patents Cigarettes with blends of plus various Pending Patent Applications very-low-nicotine tobacco and hemp Patent claims cover cigarettes comprising: • Any percentage of blends of tobacco and hemp which includes at least 2 mg hemp • N
Slide 18: Cabbacis Patent Families
Cabbacis Patent Families Very-low-nicotine cigarettes with Pods (for vaporizers) with blends of low blends of low-nicotine tobacco and hemp nicotine (or conventional) tobacco and hemp 18
Slide 19: Growth Strategy
Growth Strategy Potential to Become a Major Player in Global Nicotine-Reduction Movement U.S. Market Pathway for iBLEND • File 2 U.S. Premarket Tobacco Applications (PMTAs) at FDA 1. iBLEND cigarettes expected in mid-2027 2. iBLEND vaporizer pods expected to be filed with partner/licensee • FDA revi
Slide 20: Select Financials and Capital Raise
Select Financials and Capital Raise Current Regulation A+ Capital Raise • Targeting $7.5M (3.75 M shares at $2/share) • For Operations for at least 2 years, including G&A, remaining clinical trials, regulatory expenses, tobacco & hemp plantings, IP, machinery and unforeseen events • No warrants Clea
Slide 21: Use of Offering Proceeds (For at Least 2 Years)
Use of Offering Proceeds (For at Least 2 Years) 6% 23% 16% G&A / Working Capital R&D incuding Clinial Trials Regulatory Expenses 3% Tobacco & Hemp Plantings IP Machinery 16% 23% Unforeseen Events 13% 21
Slide 22: Investment Highlights
Investment Highlights • First-to-Market Advantage: Commercializing iBlend very-low-nicotine cigarettes and pods with hemp, ahead of FDA nicotine cap • Breakthrough Product Design: iBlend uses ~95% less nicotine and <0.3% THC hemp – compliant, non-intoxicating, and legal under the 2018 Farm Bill • Ma
Slide 23: Q&A Invest Now
Q&A Learn More and Invest at www.invest.cabbacis.com Invest Now 23
Slide 24: cabbacis.com
OTCQB: CABI Investor Relations MZ Digital Main: 716-253-6442 Email: invest@cabbacis.com cabbacis.com